目的 总结原发性肝癌患者行肝动脉化学栓塞疗法（TACE）治疗过程中术前术后的专业性护理方法与经验。 方法 对2009年3月－2010年7月收治的78例行TACE治疗的肝癌患者术前予以心理护理，术后严密观察，并对少数患者发生的疼痛、胃肠道反应和感染等症状及时进行对症处理和护理干预。 结果 78例患者均顺利完成手术，安全渡过药物反应期，术后一般状况均得到改善，好转出院。 结论 专业性护理对减少TACE术后并发症，提高手术成功率，实现可重复性治疗，获得临床满意疗效有重要作用。
【摘要】 目的 探讨磁共振动态增强扫描及磁共振弥散加权成像（diffusion weighted imaging，DWI）对肝癌经导管动脉内化学栓塞（transcatheter arterial chemoembolization，TACE）治疗后的肿瘤残余及复发的判断价值。 方法 2009年1月-2010年10月，对28例经证实的肝癌患者在TACE治疗前、治疗后3~7 d及治疗后1~2个月、3~6个月行磁共振动态增强及DWI扫描，动态测量表观弥散系数（apparent diffusion coefficient，ADC）值，与数字减影血管造影（digital substraction angiography，DSA）检查对照，评价动态增强扫描及DWI对肿瘤残留或复发的检出能力。〖HTH〗结果 对肿瘤残余及复发的显示，动态增强扫描灵敏度为90.0%，特异度为96.9%；DWI灵敏度为96.7%，特异度为93.8%；动态增强扫描与DWI相结合的灵感度为100.0%，特异度为99.5%；DSA灵敏度和特异度分别为96.7%、100.0%。TACE治疗前所有肿瘤实质的ADC值为（1.134±0.014）×10-3 mm2/s；TACE治疗后3~7 d ADC值为（1.162±0.016）×10-3 mm2/s；TACE治疗后1~2个月碘油沉积较好，无明显残余或复发病灶的ADC值为（1.175±0.015）×10-3 mm2/s，3~6个月后随访病灶ADC值为（1.179±0.017）×10-3 mm2/s；TACE治疗后1~2个月碘油沉积不完全或无明显沉积病灶ADC值为（1.147±0.016）×10-3 mm2/s，3~6个月后随访病灶实质平均ADC值（1.142±0.012）×10-3 mm2/s。 结论 将动脉增强扫描与DWI相结合可提高对TACE治疗后肝癌残余及复发判断的灵敏度及特异度；对肿瘤组织平均 ADC值的动态测量、观察可及早判断肿瘤复发的可能性。【Abstract】 Objective To evaluate the dynamic contrast-enhanced MRI and diffusion weighted imaging (DWI) in judging the remnant and recurrence on hepatocellular carcinoma (HCC) after transcatheter arterial chemoembolization (TACE). Methods Between January 2009 and October 2010, 28 patients with HCC underwent dynamic contrast-enhanced MRI and DWI before and after TACE 3-7 days, 1-2 months and 3-6 months, respectively, and the apparent diffusion coefficient (ADC) value of the tumor were also measured at above mentioned time points. The sensitivity and specificity of dynamic contrast-enhanced MRI and DWI in diagnosis of residual tumor and recurrent cancer was qualitatively evaluated by comparing with the DSA results. Results Compared with DSA, the sensitivity and specificity of dynamic contrast-enhanced MRI were 90.0% and 96.9% by revealing the remnant and recurrence of HCC, while the sensitivity and specificity of DWI were 96.7% and 93.8% respectively. Combining dynamic contrast-enhanced MRI and DWI the sensitivity and specificity were improved to 100.0% and 99.5%, respectively. The mean ADC value of tumor before and after 3-7 days of TACE were (1.134±0.014)×10-3 and (1.162±0.016)×10-3 mm2/s, respectively. The mean ADC value of tumor without and with remnant and recurrence after 1-2 months and 3-6 months follow up were (1.175±0.015)×10-3, and (1.179±0.017)×10-3 mm2/s; (1.147±0.016)×10-3 and (1.142±0.012)×10-3 mm2/s, respectively. Conclusions Combining dynamic contrast-enhanced MRI and DWI could improve the sensitivity and specificity to detect the remnant and recurrence of HCC after TACE. Measuring the ADC value during follow up of HCC patients after TACE could predict the probability of tumor recurrence.
目的:探讨经肝动脉导管注射明胶海绵碘化油乳剂治疗肝癌合并严重动静脉瘘的可行性及临床应用价值。方法:对38例肝癌动静脉瘘患者血管分别行超选择插管注射明胶海绵碘化油乳剂,造影观察动静脉瘘的栓塞率,血管再通率,副作用,并发症及生存率等指标。结果:38例肝癌动静脉瘘患者经肝动脉导管注入明胶海绵碘化油乳剂约2~10mL栓塞,栓塞后造影显示闭塞率为94.7%(36/38),4周后造影显示动静脉瘘再通率为5.56%(2/36),未见确切不良反应,肿瘤碘化油乳剂沉积好,患者6月生存率为94.7%(36/38),12月生存率为60.5%(23/38),24月生存率为21.1%(8/38)。结论:经肝动脉导管注射碘化油乳剂治疗肝癌动静脉瘘安全可靠,对瘘口要求不高,栓塞率高,再通率低,肿瘤的栓塞治疗效果好。